Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Raymond D. Meng
Observed names:
R D Meng,
R Meng,
R. D. Meng,
R. Meng,
R.D. Meng,
RAYMOND D. MENG,
RAYMOND MENG,
Raymond D Meng,
Raymond Meng
show all 9
Institution:
Genentech
Observed institutions:
National Institutes of Health,
Memorial Sloan Kettering Cancer Center,
Howard Hughes Medical Institute,
Genentech,
National Institute of Diabetes and Digestive and Kidney Diseases,
Annexon Biosciences (United States),
Instacart (United States),
University of Pennsylvania
show all 8
OpenAlex ID:
A5110163617
Works
72
Awards
1
Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study
2022
·
Byoung Chul Cho
, Delvys Rodriguez Abreu
, et al.
·
The Lancet Oncology
·
506
γ-Secretase Inhibitors Abrogate Oxaliplatin-Induced Activation of the Notch-1 Signaling Pathway in Colon Cancer Cells Resulting in Enhanced Chemosensitivity
2009
·
Raymond D. Meng
, Christopher C. Shelton
, et al.
·
Cancer Research
·
319
PDF
Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE).
2020
·
Delvys Rodriguez-Abreu
, Melissa Lynne Johnson
, et al.
·
Journal of Clinical Oncology
·
265
A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors
2016
·
Cristina Saura
, Desamparados Roda
, et al.
·
Cancer Discovery
·
195
Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells
2024
·
Xiangnan Guan
, Ruozhen Hu
, et al.
·
Nature
·
171
SKYSCRAPER-02: Tiragolumab in Combination With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage Small-Cell Lung Cancer
2023
·
Charles M. Rudin
, Stephen V. Liu
, et al.
·
Journal of Clinical Oncology
·
150
PDF
p53-Independent Upregulation of KILLER/DR5 TRAIL Receptor Expression by Glucocorticoids and Interferon-γ
2001
·
Raymond D. Meng
, Wafik S. El-Deiry
·
Experimental Cell Research
·
150
The TRAIL Decoy Receptor TRUNDD (DcR2, TRAIL-R4) Is Induced by Adenovirus-p53 Overexpression and Can Delay TRAIL-, p53-, and KILLER/DR5-Dependent Colon Cancer Apoptosis
2000
·
Raymond D. Meng
, E. Robert McDonald
, et al.
·
Molecular Therapy
·
136
A Randomized Controlled Trial of a Cardiopulmonary Resuscitation Video in Advance Care Planning for Progressive Pancreas and Hepatobiliary Cancer Patients
2013
·
Andrew S. Epstein
, Angelo E. Volandes
, et al.
·
Journal of Palliative Medicine
·
96
Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors: A Phase 1a/1b Nonrandomized Controlled Trial
2023
·
Tae Won Kim
, Philippe L. Bedard
, et al.
·
JAMA Oncology
·
92
PDF
p53-independent increase in E2F-1 expression enhances the cytotoxic effects of etoposide and of adriamycin.
1999
·
R D Meng
, P Phillips
, et al.
·
International Journal of Oncology
·
88
SKYSCRAPER-02: Primary results of a phase III, randomized, double-blind, placebo-controlled study of atezolizumab (atezo) + carboplatin + etoposide (CE) with or without tiragolumab (tira) in patients (pts) with untreated extensive-stage small cell lung cancer (ES-SCLC).
2022
·
Charles M. Rudin
, Stephen V. Liu
, et al.
·
Journal of Clinical Oncology
·
78
Abstract CT302: Phase Ia/Ib dose-escalation study of the anti-TIGIT antibody tiragolumab as a single agent and in combination with atezolizumab in patients with advanced solid tumors
2020
·
Johanna C. Bendell
, Philippe Bedard
, et al.
·
Cancer Research
·
57
A phase II, randomised study of mFOLFOX6 with or without the Akt inhibitor ipatasertib in patients with locally advanced or metastatic gastric or gastroesophageal junction cancer
2018
·
Y.-J. Bang
, Y.-K. Kang
, et al.
·
European Journal of Cancer
·
49
Abstract CT051: SKYSCRAPER-01: A phase III, randomized trial of tiragolumab (tira) + atezolizumab (atezo) versus placebo (pbo) + atezo in patients (pts) with previously-untreated PD-L1-high, locally advanced unresectable/metastatic NSCLC
2025
·
Solange Peters
, Roy Herbst
, et al.
·
Cancer Research
·
48
Bypass of abnormal MDM2 inhibition of p53-dependent growth suppression.
1998
·
R D Meng
, H Shih
, et al.
·
PubMed
·
36
A phase Ib open-label dose escalation study of the safety, pharmacokinetics, and pharmacodynamics of cobimetinib (GDC-0973) and ipatasertib (GDC-0068) in patients with locally advanced or metastatic solid tumors
2020
·
Geoffrey I. Shapiro
, Patricia LoRusso
, et al.
·
Investigational New Drugs
·
32
Phase I study of the anti-endothelin B receptor antibody-drug conjugate DEDN6526A in patients with metastatic or unresectable cutaneous, mucosal, or uveal melanoma
2019
·
Shahneen Sandhu
, Catriona M. McNeil
, et al.
·
Investigational New Drugs
·
31
LBA2 Updated analysis and patient-reported outcomes (PROs) from CITYSCAPE: A randomised, double-blind, phase II study of the anti-TIGIT antibody tiragolumab + atezolizumab (TA) versus placebo + atezolizumab (PA) as first-line treatment for PD-L1+ NSCLC
2021
·
B.C. Cho
, D. Rodriguez-Abreu
, et al.
·
Annals of Oncology
·
27
LBA-5 Phase Ib study of the anti-TIGIT antibody tiragolumab in combination with atezolizumab in patients with metastatic esophageal cancer
2021
·
Z. Wainberg
, I. Matos
, et al.
·
Annals of Oncology
·
20
PDF
Randomized phase II study of AKT blockade with ipatasertib (GDC-0068) and abiraterone (Abi) vs. Abi alone in patients with metastatic castration-resistant prostate cancer (mCRPC) after docetaxel chemotherapy (A. MARTIN Study).
2016
·
Johann S. De Bono
, Ugo De Giorgi
, et al.
·
Journal of Clinical Oncology
·
19
P77.02 Efficacy of Tiragolumab + Atezolizumab in PD-L1 IHC and TIGIT Subgroups in the Phase II CITYSCAPE Study in First-Line NSCLC
2021
·
N. Patil
, B.C. Cho
, et al.
·
Journal of Thoracic Oncology
·
18
LBA2 SKYSCRAPER-06: Efficacy and safety of tiragolumab plus atezolizumab plus chemotherapy (tira + atezo + chemo) vs pembrolizumab plus chemotherapy (pembro + chemo) in patients (pts) with advanced non-squamous non-small cell lung cancer (NSq NSCLC)
2024
·
M.A. Socinski
, D. Rodriguez Abreu
, et al.
·
Immuno-Oncology Technology
·
14
Tiragolumab Plus Atezolizumab and Chemotherapy for Advanced Nonsquamous Non–Small Cell Lung Cancer: The Phase 3 SKYSCRAPER-06 Randomized Clinical Trial
2026
·
Mark A. Socinski
, Rolf Stahel
, et al.
·
JAMA Oncology
·
11
Comparative Gene Expression Profiling in Response to p53 in a Human Lung Cancer Cell Line
1999
·
Suisui Song
, Timothy K. MacLachlan
, et al.
·
Biochemical and Biophysical Research Communications
·
9
PDF
Show more works
View as search
Works count:
72
Citation count:
2,734
H-index:
20
I10-index:
24
Year
Topic
Type